MRK•benzinga•
Biocytogen Reports Antibody Deal With Merck Whereby Co. Will Grant Merck Sole License To Evaluate Proprietary Antibodies Against At Least 3 Distinct Targets With Option To Buy Some Assets At Later Date, No Terms Disclosed
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 29, 2022 by benzinga